GenScript Demonstrates High-Throughput Measurement of Neutralization Antibody Titers in Serum Samples from SARS-CoV-2 Infected Patients

GenScript USA Inc. (Piscataway, NJ, USA) presented its newly available assay termed cPass Surrogate Virus Neutralization Test (cPassTM sVNT) at the all virtual 2020 AACC Annual Scientific Meeting held on December 13-17.

The assay permits the qualitative and quantitative evaluation of neutralizing antibodies in a simple, cost-effective, and high-throughput test. With the oncoming SARS-CoV-2 vaccination programs soon to be initiated globally, many questions have arisen concerning the efficacy and duration of protection. The focus on a subset of immune response antibodies that block and effectively neutralize the interaction between the virus and host cells has become a key measure of vaccine efficacy. However, their measurement is challenging with the pre-existing live cell neutralization tests that are considered gold standard.


Samples from SARS-CoV-2 recovered individuals exhibited differences up to 400-fold in neutralizing antibody titers demonstrating the practical application of cPass sVNT to assess strength of immune response between both infected and vaccinated individuals; level of protection against re-infection, and duration of protection post-infection/vaccination. cPass sVNT detects circulating neutralizing antibodies against SARS-CoV-2 that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein with the ACE2 cell surface receptor. This kit would be instrumental in vaccine and therapeutic development as it is suitable for all antibody isotypes and can be used to determine neutralizing antibodies in animal models without modification. The kit will also help in current COVID-19 investigations of sero-prevalence, assessment of herd immunity, longevity of protective immunity, efficacy of different vaccine candidates as well as tracking infection in animals.

Related Links:
GenScript USA Inc.